아폴로믹스 (APLM) 주가

아폴로믹스(APLM)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $23.40 (+34.72%), 시가총액 $0.03B, 52주 범위 $3.93 ~ $36.65.

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting Er

핵심 지표

• 현재가: $23.40 (+34.72%)
• 시가총액: $0.03B
• 52주 최저~최고: $3.93 ~ $36.65
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

아폴로믹스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.

아폴로믹스 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 4

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 8.15
• 순이익률: -1.24%
• 영업이익률: 4.32%

자주 묻는 질문